Pharming Group NV (PHAR NASDAQ) stock market data APIs
$9.655
-0.36(-3.6%)
as of January 17, 2025
Pharming Group NV Financial Data Overview
Price chart is built with
Anychart
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Prev. Close
10.01
Open
9.655
Volume
8 274
High
10.01
Low
9.5082
52 wk Range
6.65-13.2
Market Cap
679 M
Shares Outstanding
67 835 K
Revenue
286 M
EPS
-0.0153
Beta
0.811
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharming Group NV data using free add-ons & libraries
Get Pharming Group NV Fundamental Data
Pharming Group NV Fundamental data includes:
- Net Revenue: 286 M
- EBITDA: -3 057 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-10-24
- EPS/Forecast: -0.0025
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group NV News
New
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, ...
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
Pharming Group N.V. The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leid...
Sequana Medical announces results of Special General Meeting of Shareholders
PRESS RELEASE REGULATED INFORMATION 26 June 2023,06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023– Sequana Medical NV (Euronext Brussels: SEQ...
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023
LEIDEN, Netherlands, April 26, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries will ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
